ライフサイエンスコーパス: IgG1

1 into two other antibody formats (scFv-Fc and IgG1).

2 ort and that FcRn transported less IgG2 than IgG1.

3 serum half-lives as long as wild-type human IgG1.

4 quency, and class switching of GC B cells to IgG1.

5 lowest increase (1%) through spiked oxidized IgG1.

6 h stability equivalent to that of the parent IgG1.

7 ed cytotoxity in both murine IgG2a and human IgG1.

8 quency, and class switching of GC B cells to IgG1.

9 d as scFv-Fc with 35 produced as fully human IgG1.

10 ry IgG Fc structures, including afucosylated IgG1.

11 odies (mAbs) are based on humanized or human IgG1, 2, or 4 subclasses and engineered variants.

12 TCZ reduced total IgG and IgG1-3 and anti-HLA-total IgG and IgG3 levels, suggestin

13 Total IgG and IgG1-3 were significantly reduced post-TCZ, whereas no r

14 classes having homologous F(ab')2 C termini (IgG1/3/4).

15 with significantly higher AHA levels against IgG1/3/4.

16 tein G to deplete IgG Ab. alpha-Gal-specific IgG1-4 Ab in individuals with and without meat allergy w

17 lasma exchange were tested for total IgG and IgG1-4 by ELISA, anti-HLA-total IgG, IgG3 and IgG4, and

18 pact of TCZ treatment for cAMR on total IgG, IgG1-4 subclasses, and anti-HLA-IgG (total and subclasse

19 There were no correlations with LGI1/CASPR2-IgG1-4 subclasses.

20 hD IgG Abs of the four different subclasses (IgG1-4) with and without core fucose (i.e., 20% fucose r

21 Immunoglobulin G1 (IgG1), a subclass of human serum antibodies, is the most

22 silon directs the early choice of IgE versus IgG1, a key physiological response against parasitic inf

23 IgG1 ab1 also exhibited high prophylactic and therapeuti

24 IgG1 ab1 did not aggregate, did not exhibit other develo

25 dy-dependent cellular cytotoxicity (ADCC) as IgG1 ab1 had ADCC activity in vitro.

26 These results suggest that IgG1 ab1 has potential for therapy and prophylaxis of SA

27 aries and converted to a full-size antibody, IgG1 ab1, which competed with human ACE2 for binding to

28 s detected (seroprevalence range, 5%-35% for IgG1 and 27%-41% for IgG3), varied across study sites, a

29 ts gave low goodness-of-fit R factors for 28 IgG1 and 2748 IgG4 structures that satisfied the disulph

30 with RNAdjuvant significantly enhanced this IgG1 and additionally promoted the formation of IgG2b/c,

31 Anti-Hcp1 IgG1 and anti-OPS IgG2 had the greatest AUROCCs (0.87 an

32 ures were distinct from those for asymmetric IgG1 and asymmetric and symmetric IgG4 and were attribut

33 ration at previously intractable sites of an IgG1 and at multiple sites in the same polypeptide chain

34 ive autoantigen in fibrillary GN and suggest IgG1 and classic complement effector pathways as likely

35 ants controlled infection better than murine IgG1 and humanized IgG1-N297Q variants.

36 slightly higher titers of HA stalk-specific IgG1 and IgA Abs in sera from uninfected participants th

37 lizing antibodies and enhanced high affinity IgG1 and IgA antibodies.

38 in H1N1-specific neutralization and binding IgG1 and IgA responses.

39 ne effector functions, mediated primarily by IgG1 and IgA1.

40 ediated inflammation, including higher serum IgG1 and IgE levels, more IL-4, IL-13 mRNA expression in

41 d FcRn mediated transcytosis of V(H)-matched IgG1 and IgG2 and mutated variants thereof lacking Fc-ga

42 IgG1 and IgG2 have similar half-lives, yet IgG2 displays

43 cRn binding residues being preserved between IgG1 and IgG2.

44 vant activity and led to saponin 3's similar IgG1 and IgG2a activities to QS-21's, indicating that th

45 h the VC2-EHV-1-gD vaccine stimulated robust IgG1 and IgG2a antibodies after three vaccinations (P <

46 ter membrane protein OmpD, which induce both IgG1 and IgG2a in mice, provide protection to S.

47 pretreated mice had decreased IgE as well as IgG1 and IgG2a levels and Treg numbers were significantl

48 Its IgG1 and IgG2a production is similar to that of GPI-0100

49 retain the adjuvant's activity in enhancing IgG1 and IgG2a productions, albeit the activity is lower

50 mune response with a significant increase of IgG1 and IgG2a responses in mice at a reduced dose compa

51 A mice had elevated serum IgM with decreased IgG1 and IgG2a whether mice were challenged at 7 or 28 d

52 t affect anti-Leishmania antibody (IgM, IgG, IgG1 and IgG2a) or IL-10 production, but anti-PD-1 treat

53 lr/wild-type mice led to a decrease of serum IgG1 and IgG2c but not IgG3, as well as decreased IgM, a

54 owed significantly higher alpha-gal-specific IgG1 and IgG3 Ab than nonallergic individuals, whereas t

55 ord serum samples were assayed for levels of IgG1 and IgG3 specific for MSP119, MSP2 (both allelic fa

56 IgG1 and IgG3 subclasses of IgG are potent effectors of

57 lls and antibody production predominantly of IgG1 and IgG3 subclasses.

58 howed a prevalence of cytophilic antibodies (IgG1 and IgG3), that seem to have an essential role in p

59 ased erythrocyte lysis was observed with the IgG1 and IgG3, respectively, but no increase with IgG2 a

60 notype, and the IgG exclusively consisted of IgG1 and IgG3.

61 In this study, mAbs A-C of IgG1 and IgG4 (immunoglobulin G, IgG) isotypes with oxid

62 Immune complexes with subclasses IgG1 and IgG4 can in vitro be generated by plate absorpt

63 They mainly produce GAD65 antibodies of the IgG1 and IgG4 subclasses and are as abundant as B cells

64 the detection by flow of IgM and IgG (mostly IgG1 and IgG4) anti-CD4+ cell Abs in 50% of the patients

65 492 and 190,437 acceptable conformations for IgG1 and IgG4, respectively, joint x-ray and neutron sca

66 l differences in Fc receptor binding between IgG1 and IgG4.

67 ch was significantly reduced by depletion of IgG1 and less so by IgG4 depletion.

68 FQ) vaccine regimen elicited higher anti-Env IgG1 and lower IgG4 antibody levels in serum, showing fo

69 ification of allergen-specific serum IgE and IgG1 and of the mast cell protease MCPT1, as well as spl

70 ctively bound to target-molecule-bound mouse IgG1 and rabbit IgG primary antibodies, whereas the bisp

71 MG1Nb-Nluc-ABD, mutually bound to both mouse IgG1 and rabbit IgG primary antibodies.

72 fusion protein composed of the Fc region of IgG1 and the extracellular domain of CTLA4 (also known a

73 OVA application induced higher OVA-specific IgG1 and total IgE in serum, and increased eosinophilia

74 ved pharmacokinetics relative to both native IgG1 and widely used half-life extension variants, both

75 t Asn-77 (equivalent to Asn-297 in the Fc of IgG1) and Asn-236 (equivalent to Asn-563 in the tail pie

76 cific IgG1(+) germinal center B cells, serum IgG1, and anaphylaxis that was mediated by the alternati

77 mice, produce transcripts that generate IgM, IgG1, and IgE in an alternative splice form bias hierarc

78 on resulted in higher serological total IgG, IgG1, and IgG2a anti-alpha-syn levels.

79 itis by downregulating immunoglobulin (Ig)G, IgG1, and IgG2a production.

80 serum IgA responses but also enhanced serum IgG1, and IgG2b responses.

81 tched" heavy and light chains were cloned as IgG1, and those of high affinity for specific SAEs, assa

82 proteins and complexes (PEG-GCSF; an IgG1k; IgG1- and IgG2-biotin covalent conjugates; the membrane

83 tion and histamine predominance in mice with IgG1- and IgG2b-induced anaphylaxis correlated with the

84 Serum anti-GD2 (immunoglobulin G1 [IgG1] and IgM) and anti-GD3 (IgG1) titers showed notable

85 ) 3F7.A10 to BALB/c mice with high titers of IgG1 anti-3F7.A10 led to glomerular deposits of IgG1/IgG

86 Clinical testing of a human IgG1 anti-CD27 Ab, varlilumab (clone 1F5), is ongoing in

87 mouse mast cell protease 1), increased serum IgG1 anti-EW and IgE levels, and increased IL-4 and IL-1

88 e-DNA subunit of chromatin, four elicited an IgG1 anti-mAb response and one mAb was nonimmunogenic.

89 that the titers of the total IgG and subtype IgG1 anti-SjHSP60 antibodies were positively correlated

90 and pharmacokinetics of TY014, a fully human IgG1 anti-yellow fever virus monoclonal antibody.

91 ce immunized with recombinant LJM17 produced IgG1 antibodies (human IgG4 homolog) that strongly cross

92 t protective role of functional IgE-blocking IgG1 antibodies in the early phase of allergy treatment.

93 In contrast, bovine IgG2 and human IgG1 antibodies were cleaved rapidly into Fab and smalle

94 linical studies with 4 (89)Zr-labeled intact IgG1 antibodies were collected, resulting in a total of

95 y cross-reacted with recombinant DSG1; these IgG1 antibodies were inhibited by LJM17, LJM11, and DSG1

96 Bovine IgG1 antibodies, the primary component of AVX-470, were

97 lected and used to construct isotype-matched IgG1 antibodies, which were then expressed in mammalian

98 d production of anti-trinitrophenyl chloride IgG1 antibodies.

99 nt immunotherapy, induces immunoglobulin G1 (IgG1) antibodies and antigen-specific T cell responses i

100 e shown that a new CXCR4 receptor antagonist IgG1 antibody (PF-06747143) binds strongly to AML cell l

101 Th2-type isotype IgG1 antibody levels were associated with protective imm

102 osomal vaccine administration elevated IgG2c/IgG1 antibody ratio, indicative of augmented OVA-specifi

103 tigen (PMSA) and is comprised of a humanized IgG1 antibody site-specifically conjugated to tesirine (

104 ave described Pr20, a TCR mimic (TCRm) human IgG1 antibody that recognizes the cell-surface ALY pepti

105 pplication of the computational method to an IgG1 antibody under mild denaturing conditions indicates

106 ctionLess (SEFL) antibody was designed as an IgG1 antibody with a constant region that lacks the abil

107 human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic ur

108 molgus FcgammaRs compared with the wild-type IgG1 antibody.

109 oteome of fibrillary GN cases also contained IgG1 as the dominant Ig and proteins of the classic comp

110 tleneck, we fused GCSF with the Fc domain of IgG1 at the C terminus (GCSF-Fc) and with the maltose bi

111 This study demonstrates that T-bet(high) IgG1(+) B cells are triggered by IFNgamma and TLR9 signa

112 Our data demonstrate that IgG1(+) B-cell immunity against food allergens in epicut

113 ment outcomes in VL, and the first use of an IgG1-based RDT using the rK39 antigen for the discrimina

114 Here an attempt was made to engineer an IgG1-based scaffold lacking effector function but with s

115 , Bet v 1 was the more potent competitor for IgG1 binding to Mal d 1 in post-rBet v 1 SLIT sera.

116 In competition ELISA, IgG1 binding to Mal d 1 in post-rMal d 1 SLIT sera was f

117 IgG1 binding to rMal d 1 was competed with rMal d 1 and

118 FcgammaRIV and inhibitory FcgammaRIIB; mouse IgG1 binds only FcgammaRIII and FcgammaRIIB.

119 thod for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).

120 ort the unexpected finding that mice lacking IgG1, but not IgG2a, are substantially less protected af

121 ore fucose alters type I FcgammaR binding of IgG1 by modulating the Fc's affinity for FcgammaRIIIa, t

122 Ab comprised of a TLQ mutant and a wild-type IgG1 can be efficiently separated from contaminating par

123 Thus, the Th2-associated isotype IgG1 can play a role in protection against Th1-associate

124 G clones, including a non-natural bispecific IgG1 candidate, targeting Pseudomonas aeruginosa.

125 affinity IgE is produced by the switching of IgG1 cells to IgE.

126 e interdomain protein interface of the human IgG1 CH3 dimer with the protein interface of the constan

127 TCR alpha/beta constant domain pair and the IgG1 CH3 homodimer was evidenced by X-ray crystallograph

128 This infliximab-bovine IgG1 chimera (bovinized infliximab) retained the antigen

129 ii) efficacy in vitro and in vivo of a human IgG1 chimeric derivative of MAb 2C7 (2C7-Ximab) with a c

130 21 was attenuated by CD40 signaling, whereas IgG1 class switch recombination was potentiated by IL-21

131 The data show elevated specific IgE and IgG1 concentrations in the blood of OVA-sensitized Cyp27

132 mpurities in Fd, Fc/2, and LC subunits of an IgG1 consistently across multiple samples.

133 cisely defined ICs of the subclasses IgG4 or IgG1 constructed by two independent methods.

134 tion of BM cells from PF-06747143-treated or IgG1 control-treated animals showed that leukemic progen

135 s 24 h after a single dose of conatumumab or IgG1 control.

136 ant IgG3 anti-V2 MAbs were compared to their IgG1 counterparts.

137 expanded, somatically hypermutated IgM+ and IgG1+ CSF B cells were associated with inflammation, blo

138 The decreased protection in IgG1-deficient mice correlates with less efficient bacte

139 IgG1-deficient mice produce more porin-specific IgG2a, r

140 mpanied by high levels of alpha-gal-specific IgG1 devoid of IgE-blocking activity.

141 or absence of galactose on the Fc glycan of IgG1 did not alter FcgammaRIIIa or FcRn binding, half-li

142 sition 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content

143 ology between proposed RF target epitopes in IgG1 Fc and the ACPA target fibrinogen.

144 TXB2 was fused to a human IgG1 Fc domain (hFc) or to the amyloid-beta (Abeta) anti

145 multi-specific VHH antibodies fused to human IgG1 Fc domains based on the epitope predictions for lea

146 The IgG1 Fc fragments containing complex sialylated glycans

147 No differences in IgG1 Fc glycan profiles and minimal differences in IgG2

148 eries of sequentially truncated high-mannose IgG1 Fc glycoforms, we found that the C'E loop and the C

149 e truncated glycoforms, suggesting a role of IgG1 Fc N-glycan in optimizing the interface with the Fc

150 ltaB7-H6-based NK cell engagers with a human IgG1 Fc part competent in Fc receptor binding resulted i

151 Using mutant human IgG1 Fc regions engineered not to engage complement or F

152 glycans can modulate the binding affinity of IgG1 Fc to Fc gamma receptors, but it is unclear how the

153 display technology, we engineered the human IgG1 Fc to increase its affinity for TRIM21 by 100-fold.

154 ly, we demonstrated that aglycosylated human IgG1 Fc variants can engage the human FcgammaRII class o

155 nd could be inhibited by pre-incubation with IgG1 Fc.

156 n type composition of the immunoglobulin G1 (IgG1) Fc fragment.

157 at Asn-297 on the structure and function of IgG1-Fc is well documented; however, whether the N-linke

158 udy, we compare two panels of glycan-adapted IgG1-Fc mutants expressed in either the human endothelia

159 The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structures (h

160 nalysis demonstrated specific binding of the IgG1 format to cells expressing membrane-bound CoV-2 spi

161 This process generated allergen-specific IgG1(+) germinal center B cells, serum IgG1, and anaphyl

162 consists of residues Pro238 to Lys340 of the IgG1 heavy chain sequence.

163 ody (Rb), that specifically recognizes human IgG1 (hIgG1).

164 ces from these regions, including the bovine IgG1 hinge region and a predicted disulfide bonding moti

165 variant, CD32aH more avidly bound human (h) IgG1 IC and formed a ternary complex with the neonatal F

166 Our data indicate that B cell activation and IgG1/IgE production is triggered by microbial and dietar

167 The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structu

168 tures rationalize the existence of the human IgG1, IgG2, and IgG4 subclasses and explain the receptor

169 duced comparable levels of rMal d 1-specific IgG1, IgG2, IgG3, and IgG4 antibodies.

170 ecretion of the inflammatory factors such as IgG1, IgG2, IgM, IL-6 and PMPhi phagocytosis, stimulatio

171 11 different peptide backbones, derived from IgG1, IgG2/3, IgG4, IgA1, IgA2, and the joining chain fr

172 d with TGFbeta1-mim had lower levels of IgE, IgG1, IgG2a and higher levels of IgA antibodies than con

173 etic Biology adjuvants also elicited similar IgG1, IgG2a, and total IgG levels compared to marine and

174 ing sensitization led to strong induction of IgG1, IgG2a, IgG2b, and IgG3, decrease of specific and t

175 Mice were sensitized with IgG1, IgG2a, or IgG2b anti-trinitrophenyl mAbs and chall

176 1 anti-3F7.A10 led to glomerular deposits of IgG1/IgG2a complexes.

177 sate (YPL), and F1 antigen and more balanced IgG1:IgG2a/IgG2b-derived Th1 and Th2 responses than LcrV

178 rticles elicited both IgM and class-switched IgG1, IgG2b, and IgG3 autoreactive Abs that depended on

179 , the liposomal particles also elicited IgM, IgG1, IgG2b, and IgG3 responses that were comparable in

180 Frequencies of isotype switching to IgG1, IgG2b, IgG2c, and IgG3 were the same as C57BL/6 co

181 Of these women, 71.4% were IgG1+IgG3+, consistent with more recent chlamydia resolu

182 IgE, IgG1, IgG3 and IgA1 transcripts showed reduced somatic h

183 utically-useful properties compared with the IgG1, IgG3, and IgG4 antibody subclasses.

184 IgG1, IgG3, and IgM were significantly correlated with C

185 Specific and total IgG1, IgG4, IgA, and IgE from plasma as well as culture

186 nt of allergen-specific cellular and humoral IgG1(+) immunity may help to identify individuals at ris

187 indirect help for B-cell class switching to IgG1 in both transnuclear and wild-type mice.

188 We present strong evidence for the use of IgG1 in monitoring treatment outcomes in VL, and the fir

189 d the production of antigen-specific IgE and IgG1 in serum.

190 to originate from the interaction of Fab and IgG1 in small soluble oligomers, or through the rapid co

191 I IFN responses are controlled by IgG3, and IgG1 is able to regulate both.

192 We further demonstrate that GP-specific IgG1 is by far the seroprevalent subclass that retained

193 n 4 (IL-4), hence class switching to IgE and IgG1, is not fully understood.

194 Tildrakizumab is a high-affinity, humanised, IgG1 kappa antibody targeting interleukin 23 p19 that re

195 de bonds and cysteine-related variants in an IgG1 knob-into-hole bispecific antibody.

196 reas IgA was strongly induced (20-fold), and IgG1 levels remained unchanged.

197 ly stimulated both the humoral (>32 times of IgG1 levels vs alum) and the cell-mediated immune respon

198 ivity, total cell count and specific IgE and IgG1 levels were lower in SAM11-administered mice.

199 transport of IgG2 + Gly236 was increased to IgG1 levels.

200 ne responses and serum allergen-specific IgE/IgG1 levels.

201 investigate serum anti-CT immunoglobulin G1 (IgG1; long-lived response) and immunoglobulin G3 (IgG3;

202 ed in detail can be applied to any humanized IgG1 mAb biotherapeutic for preclinical study support.

203 ly, Fc engineering of human glycan-targeting IgG1 mAb confers proinflammatory direct cell killing and

204 region and His231 in the hinge region of the IgG1 mAb heavy chain.

205 clotron mass spectrometer to characterize an IgG1 mAb molecule conjugated with biotin via native lysi

206 N-linked glycan heterogeneity present on an IgG1 mAb molecule containing two distinct N-linked glyco

207 witching studies, murine IgG2a and humanized IgG1 mAb variants controlled infection better than murin

208 folding of a recombinant monoclonal antibody IgG1 (mAb) was measured with differential scanning calor

209 the Fc regions of fully human and humanized IgG1 mAbs as well as of Fc-fusion proteins.

210 ominant ADCP activity compared to a panel of IgG1 MAbs.

211 re we investigate the function of subsets of IgG1 memory B cells in IgE production and find that two

212 generated via class-switch recombination in IgG1 memory B cells without additional somatic hypermuta

213 IgE production and find that two subsets of IgG1 memory B cells, CD80(+)CD73(+) and CD80(-)CD73(-),

214 lyzed allergen-specific germinal centers and IgG1(+) memory B cells by flow cytometry, evaluated humo

215 ite for sensitization, the allergen-specific IgG1(+) memory compartment predominantly exhibited an im

216 best-fit structures showed that the best-fit IgG1 models had a greater separation between the centers

217 re of protein therapeutics and in particular IgG1 monoclonal antibodies (mAbs).

218 An IgG1 monoclonal antibody (mAb) purified by Protein A col

219 high-molecular weight (HMW) fractions of an IgG1 monoclonal antibody (mAb).

220 ety and efficacy of belimumab, a fully human IgG1 monoclonal antibody targeting the cytokine B cell-a

221 Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting

222 mpared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by

223 ection better than murine IgG1 and humanized IgG1-N297Q variants.

224 ally fusing luciferase (Nluc) with antimouse IgG1 nanobody (MG1Nb) and antibody-binding domain (ABD),

225 rapid coalescence of pre-existing monomeric IgG1 nuclei into a dead-end aggregate, rather than throu

226 ated SEE-induced basophil degranulation, and IgG1 or antigen-binding fragments of each anti-SEE enhan

227 pensity to acquire Fab glycans compared with IgG1 or IgA.

228 mpared with wild-type mice, but not those of IgG1 or IgA.

229 psilon/epsilon mice, which initially produce IgG1 or IgE from their respective native genomic configu

230 IgG1 or IgG enzyme-linked immunosorbent assays (ELISAs)

231 ctional and preferentially recognized either IgG1 or IgG2.

232 d on identical murine backbones as either an IgG1 or IgG2a subclass and evaluated for binding to mult

233 Cs), but the role of the specific subclasses IgG1 or IgG4 in this phenotypic and functional change is

234 Post-SLIT sera depleted of IgG1 or IgG4 were compared for their IgE-blocking activi

235 Alternatively, immune complexes with IgG1 or IgG4 were formed using protein L.

236 pecific ICs, plates were coated with myeloma IgG1 or IgG4, or with grass pollen allergen Phl p 5 foll

237 llowed by recombinant human Phl p 5-specific IgG1 or IgG4.

238 n (SHM) was strikingly higher, especially in IgG1 (p < 0.0001).

239 fic germinal centers (23.3 days), IgE(+) and IgG1(+) PCs (60 and 234.4 days, respectively), and clini

240 subclass composition changed over time, with IgG1 persisting, IgG3 rapidly declining, and IgG4 appear

241 nalysis indicates that high affinity IgE and IgG1 plasma cells differentiate from rare CD80(+)CD73(+)

242 Addition of OMP-1-specific huMAb EHRL-15 (IgG1) prevented infection by blocking attachment/entry,

243 20 million cells/mL) perfusion culture of an IgG1-producing Chinese hamster ovary (CHO) cell line for

244 ations for aberrant antigen-specific IgE and IgG1 production in response to immunization with the mod

245 ression modeling predicted that CSP-specific IgG1 promote OPA, and that CSP-specific IgG4 interferes

246 For an IgG1 protein spiked with 1000 ppm HCP standards, we dete

247 reliable and clog-free cell retention, high IgG1 recovery (>99%) and cell viability (>97%).

248 Anti-EMP2 IgG1 reduced the expression and activity of ALDH and cor

249 that the total IgG response switched from an IgG1 response to an IgG3 response after infection with L

250 RDTs provided strong evidence for decreased IgG1 responses in patients who had successful treatment

251 prior BCG vaccination promoted high-affinity IgG1 responses that neutralized viral infection.

252 fic IgE responses against allergens, whereas IgG1 responses to allergens remain unaffected.

253 er IL-4 production with increased anti-viral IgG1 responses.

254 ISAs) with rK39 or lysate antigens and novel IgG1 rK39 rapid diagnostic tests (RDTs) were assessed wi

255 Furthermore, both IgG1 rK39 RDTs (n = 38) and ELISAs showed a highly signi

256 Novel IgG1 rK39 RDTs provided strong evidence for decreased Ig

257 ines restricting production of afucosylated, IgG1 RNNIg during infection may prevent ADE of DENV dise

258 r than or equivalent to that of the parental IgG1 scaffold.

259 OVA-IgE and OVA-IgG1 serum levels were not significantly altered by L si

260 The resulting asymmetric IgG1 solution structures resembled its crystal structure

261 amples (n = 37 pairs), ELISAs with rK39- and IgG1-specific conjugates gave a far more discriminative

262 RI receptor binding compared to our best-fit IgG1 structures with fewer clashes and stronger receptor

263 maRI reporter response and GP-specific total IgG1 subclass correlated in the studied group of Ebola s

264 s CD4(+) Th cell-dependent, dominated by the IgG1 subclass, and Id specific.

265 broadly neutralizing antibody from the major IgG1 subclass, PGZL1, which shares germline V/D-region g

266 ammaRIIIA due to afucosylated Fc glycans and IgG1 subclass.

267 mab prevented the recruitment of CXCR3(high) IgG1(+) subsets, corresponding to their increased abilit

268 lated T-bet and CXCR3, and was essential for IgG1 switching.

269 alylation triggers conformational changes of IgG1 that enable interactions with type II FcgammaRs; th

270 human and rhesus IgG and with Fc variants of IgG1 that enhance binding to FcgammaR2A or FcgammaR3A.

271 dependent bispecific (TDB) full-length human IgG1 therapeutic antibody targeting CLL-1 that could pot

272 cancer is lacking, the ability of anti-EMP2 IgG1 therapy to reduce primary and secondary tumor forma

273 Multivariable analyses showed that anti-GD2-IgG1 titer >= 150 ng/mL by week 8 was associated with fa

274 There was an association between IgG1 titer and SNP rs3901533 of dectin-1, the beta-gluca

275 Higher anti-GD2-IgG1 titer was associated with improved survival.

276 lpha-galactosylceramide shows enhanced fecal IgG1 titers in iNKT cell-sufficient mice.

277 unoglobulin G1 [IgG1] and IgM) and anti-GD3 (IgG1) titers showed notable increases following the init

278 lia-like cells in the presence of a specific IgG1 to C. neoformans capsular polysaccharide.

279 The binding of human IgG1 to human Fc gamma receptors (hFcgammaRs) is highly

280 cal mechanism of the interaction of 10 human IgG1 to human FcRn.

281 down modulation of FcgammaRII compared with IgG1 treated cells (P = 0.0335) or untreated cells (P <

282 creased from baseline in conatumumab- versus IgG1-treated COLO205 and HT29 tumor-bearing mice (P = 0.

283 7-fold from baseline in conatumumab- versus IgG1-treated control mice (P < 0.001), in good correlati

284 RNNIg enriched for afucosylated IgG1 triggered platelet reduction in vivo and was a sign

285 unit vaccine induced moderate virus-specific IgG1, vaccination together with RNAdjuvant significantly

286 Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antag

287 inary antitumour activity of ramucirumab (an IgG1 VEGFR-2 antagonist) combined with pembrolizumab (an

288 th docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient popul

289 standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untr

290 wild-type (WT) anti-HIV-1 immunoglobulin G1 (IgG1) versus those given a Fc-Null variant of the same a

291 MOG-IgG1 was identified in 25% of RION, 25% of CRION, 10% of

292 IgG3, followed by IgG1, was the predominant IgG subclass detected (seropre

293 ations in 23 genes on papain-specific IgE or IgG1 were verified.

294 m-precipitated proteins and helminths induce IgG1, whereas Th1 Ags, such as Salmonella Typhimurium, p

295 nd Q311R or "TLQ") in the Fc region of human IgG1 which disrupt interaction with protein A while enha

296 rified 5B9, a monoclonal chimeric anti-PF4/H IgG1, which led to the formation of single cleaved 5B9 (

297 mmaRs and C1q on the IgG-Fc largely overlap, IgG1 with a deletion of G236 only silences FcgammaR-medi

298 Transport of IgG1 with a shortened lower hinge (DeltaGly236, absent i

299 nature, including an increased likelihood of IgG1 with afucosylated Fc glycans.

300 Chimeric mAb 2C7 (human immunoglobulin G1 [IgG1]) with an E430G Fc modification that enhances Fc:Fc